Results 71 to 80 of about 742,288 (358)
Rhizoma Coptidis: A Potential Cardiovascular Protective Agent [PDF]
Frontiers in Pharmacology, 2016 أمراض القلب والأوعية الدموية (CVDs) هي من بين الأسباب الرئيسية للاعتلال والوفيات في كل من العالم المتقدم والنامي. Rhizoma coptidis (RC)، المعروف باسم Huang Lian في الصين، هو الجذمور المجفف للنباتات الطبية من عائلة Ranunculaceae، مثل Coptis chinensis Franch و C. deltoidea C.Y. Cheng et Hsiao و C. teeta wall الذي استخدمه الأطباء الطبيون الصينيون لأكثر من
Hui-Li Tan +12 more
openaire +3 more sources
Aging and Cancer, EarlyView.Natural products target the aging kidney in diabetic nephropathy by restoring the AMPK–SIRT1–Nrf2 axis, reducing oxidative stress, inflammation, fibrosis, and cellular senescence while enhancing mitochondrial biogenesis and antioxidant defenses.
Sherif Hamidu +8 more
wiley +1 more source
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu +9 more
wiley +1 more source
International Journal of Endocrinology, 2018 Background. Atherosclerotic cardiovascular disease (ASCVD) is a major cause of death among patients with diabetes but can be improved by certain hypoglycemic agents.
Yuchao Wu +5 more
doaj +1 more source
Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]
, 2017 Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B. +7 more
core +2 more sources
Novel Antiplatelet Agents in Cardiovascular Disease
Journal of Cardiovascular Pharmacology and Therapeutics, 2020 Antiplatelet therapy reduces atherothrombotic risk and has therefore become a cornerstone in the treatment of cardiovascular disease. Aspirin, adenosine diphosphate P2Y12 receptor antagonists, glycoprotein IIb/IIIa inhibitors, and the thrombin receptor blocker vorapaxar are effective antiplatelet agents but significantly increase the risk of bleeding.
Maximilian Tscharre +2 more
openaire +2 more sources
Cardiovascular Management in Pregnancy [PDF]
Circulation, 2015 Thrombotic complications of pregnancy are a major cause of morbidity and mortality to the mother and fetus. Pulmonary embolism is a leading cause of maternal death and accounts for 10.3% of all maternal deaths in the United States.1,2 Overall, pregnancy increases the risk of venous thromboembolism (VTE) 5-fold, with an additional increase in risk in ...
Christina D, Yarrington +2 more
openaire +2 more sources
Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To describe the use of central stimulants and amantadine for fatigue in MS and evaluate a potential association with reduced work loss in people with MS. Methods We conducted a nationwide, matched, register‐based cohort study in Sweden (2006 to 2023) using national registers with prospective data collection.
Simon Englund +3 more
wiley +1 more source
From glucose lowering to treatment of cardiovascular disease: the repositioning of glucose-lowering agents [PDF]
, 2020 Massimiliano Caprio +2 more
openalex +1 more source
Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide [PDF]
, 2001 Background: The sulfonylurea glibenclamide (Glib) abolishes the cardioprotective effect of ischemic preconditioning (IP), presumably by inhibiting mitochondrial KATP channel opening in myocytes. Glimepiride (Glim) is a new sulfonylurea reported to affect
Baxter, G.F. +5 more
core